Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy + Checkpoint Inhibitors in Advanced Ovarian Cancer
NCT03287674Phase 2Completed
- Start
- Oct 2017
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GC101 TIL + pembrolizumab in Malignant ovarian neoplasm (OC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC). Started Oct 2017; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
Malignant ovarian neoplasm (OC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03287674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287674.